Emerging AG Inc

Pacylex Pharmaceuticals Inc. is an emerging biotech oncology company based in Edmonton, AB, dedicated to revolutionizing cancer care through innovative therapies. Specializing in developing a first-in-class, daily, oral cancer therapy, Pacylex focuses on disrupting myristoylation - a crucial process for cancer cell survival and proliferation. With a strong emphasis on N-myristoyltransferase (NMT) inhibition therapy, Pacylex leads the way in clinical development with multiple Phase 2a programs in progress. Their flagship product, zelenirstat, an orally bioavailable myristoylation inhibitor, shows promising results in treating various solid tumor cancers and lymphomas, offering a potential alternative to traditional chemotherapies and immunotherapies. Pacylex's cutting-edge approach targets urgent needs in cancer care, aiming to improve survival rates for patients with critical conditions such as acute myeloid leukemia and lung cancer. By eliminating tumors and inhibiting cancer growth in animal models, Pacylex Pharmaceuticals strives to bring hope to those facing daunting prognoses. Generated from the website content

Chenomx, Inc., based in Edmonton, AB, specializes in mixture analysis for applications in life sciences, including metabolomics, food nutrition, and cell culture research. Their innovative NMR analysis software, combined with comprehensive spectral reference libraries, provides researchers with precise and reliable identification and quantification of metabolites within complex biological mixtures. With a user-friendly interface and advanced deconvolution methods, Chenomx's software enhances the accessibility of NMR metabolomics for researchers at various levels. The company also offers NMR analysis services, supporting a wide range of applications from drug metabolism to biomarker discovery, making it a critical resource in the field of metabolomics. Generated from the website